Wikidata

(Q66406275)

English

Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

clinical trial

In more languages

Statements

title
A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas (English)
0 references
sponsor
Novartis
0 references
country
Canada
0 references
Israel
0 references
Japan
0 references
Singapore
0 references
Spain
0 references
start time
22 July 2016
0 references
end time
5 December 2019
0 references
number of participants
92
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q66406275&oldid=2076003598"